Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 652

1.

Reprint of: Virus-Specific T Cells: Broadening Applicability.

Barrett AJ, Prockop S, Bollard CM.

Biol Blood Marrow Transplant. 2018 Mar;24(3S):S1-S6. doi: 10.1016/j.bbmt.2017.12.787. Review.

PMID:
29425515
2.

Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.

Lissina A, McLaren JE, Ilander M, Andersson EI, Lewis CS, Clement M, Herman A, Ladell K, Llewellyn-Lacey S, Miners KL, Gostick E, Melenhorst JJ, Barrett AJ, Price DA, Mustjoki S, Wooldridge L.

Sci Rep. 2018 Feb 7;8(1):2534. doi: 10.1038/s41598-017-18062-x.

3.

Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation.

Cantilena CR, Ito S, Tian X, Jain P, Chinian F, Anandi P, Keyvanfar K, Draper D, Koklanaris E, Hauffe S, Superata J, Stroncek D, Muranski P, Barrett AJ, Battiwalla M.

Biol Blood Marrow Transplant. 2018 Mar;24(3):460-466. doi: 10.1016/j.bbmt.2017.11.028. Epub 2017 Nov 29.

PMID:
29197677
4.

The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database.

Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, Finn RD.

Nucleic Acids Res. 2018 Jan 4;46(D1):D624-D632. doi: 10.1093/nar/gkx1134.

5.

Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study.

Shanis D, Anandi P, Grant C, Bachi A, Vyas N, Merideth MA, Pophali PA, Koklanaris E, Ito S, Savani BN, Barrett AJ, Battiwalla M, Stratton P.

Bone Marrow Transplant. 2018 Jan;53(1):78-83. doi: 10.1038/bmt.2017.210. Epub 2017 Oct 16.

PMID:
29035398
6.

Virus-Specific T Cells: Broadening Applicability.

Barrett AJ, Prockop S, Bollard CM.

Biol Blood Marrow Transplant. 2018 Jan;24(1):13-18. doi: 10.1016/j.bbmt.2017.10.004. Epub 2017 Oct 12. Review.

PMID:
29032062
7.

Introduction and overview.

Dominici M, Zhang N, Barrett AJ.

Cytotherapy. 2017 Nov;19(11):1253-1255. doi: 10.1016/j.jcyt.2017.08.005. Epub 2017 Sep 19. No abstract available.

PMID:
28939052
8.

The importance of natural killer cell killer immunoglobulin-like receptor-mismatch in transplant outcomes.

Stringaris K, Barrett AJ.

Curr Opin Hematol. 2017 Nov;24(6):489-495. doi: 10.1097/MOH.0000000000000384. Review.

PMID:
28817402
9.

Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated Fusarium solani infection.

Sheela S, Ito S, Strich JR, Manion M, Montemayor-Garcia C, Wang HW, Oetjen KA, West KA, Barrett AJ, Parta M, Gea-Banacloche J, Holland SM, Hourigan CS, Lai C.

Leuk Res Rep. 2017 Jul 18;8:4-6. doi: 10.1016/j.lrr.2017.07.001. eCollection 2017.

10.

Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemia.

Montemayor-Garcia C, Coward R, Albitar M, Udani R, Jain P, Koklanaris E, Battiwalla M, Keel S, Klein HG, Barrett AJ, Ito S.

Transfusion. 2017 Sep;57(9):2136-2139. doi: 10.1111/trf.14201. Epub 2017 Jun 26.

PMID:
28653329
11.

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia.

Jain P, Klotz J, Dunavin N, Lu K, Koklanaris E, Draper D, Superata J, Chinian F, Yu Q, Keyvanfar K, Wong S, Muranski P, Barrett AJ, Ito S, Battiwalla M.

Leuk Res Rep. 2017 Apr 13;7:40-44. doi: 10.1016/j.lrr.2017.04.003. eCollection 2017.

12.

Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.

Anandi P, Tian X, Ito S, Muranski P, Chokshi PD, Watters N, Chawla U, Hensel N, Stroncek DF, Battiwalla M, Barrett AJ.

Cytotherapy. 2017 Jun;19(6):735-743. doi: 10.1016/j.jcyt.2017.03.010. Epub 2017 Apr 7.

PMID:
28395942
13.

High angiopoietin-2 and suppression of tumorigenicity-2 levels correlate with onset of sinusoidal obstructive syndrome-implication for the utility of serial biomarker monitoring.

Nunes AT, Jain P, Kleiner DE, Shah NN, Anandi P, Chinian F, Muranski P, Battiwalla M, Barrett AJ, Ito S.

Bone Marrow Transplant. 2017 Jun;52(6):926-928. doi: 10.1038/bmt.2017.38. Epub 2017 Mar 13. No abstract available.

PMID:
28287645
14.

Antibody darts on target for acute myelogenous leukemia.

Barrett AJ.

Ann Transl Med. 2017 Feb;5(4):80. doi: 10.21037/atm.2017.01.54. No abstract available.

15.

Transplant biomarkers ready for the clinic?

Barrett AJ.

Blood. 2017 Jan 12;129(2):137-139. doi: 10.1182/blood-2016-11-751842. No abstract available.

16.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

17.

A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.

Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K.

Blood. 2017 Feb 9;129(6):740-758. doi: 10.1182/blood-2016-05-713347. Epub 2016 Nov 7.

18.

Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.

Zhao X, Tian X, Kajigaya S, Cantilena CR, Strickland S, Savani BN, Mohan S, Feng X, Keyvanfar K, Dunavin N, Townsley DM, Dumitriu B, Battiwalla M, Rezvani K, Young NS, Barrett AJ, Ito S.

Br J Haematol. 2016 Nov;175(3):427-439. doi: 10.1111/bjh.14244. Epub 2016 Jul 19.

19.

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.

Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K.

Blood. 2016 Dec 15;128(24):2819-2823. Epub 2016 Oct 19.

20.

Toxoplasmosis encephalitis with immune-reconstitution inflammatory syndrome in an allogeneic stem cell transplant patient: a case report.

Gatti-Mays ME, Manion M, Bowen LN, Brown GT, Danner RL, Khan O, Nath A, Battiwalla M, Barrett AJ, Ito S.

Bone Marrow Transplant. 2016 Dec;51(12):1622-1624. doi: 10.1038/bmt.2016.230. Epub 2016 Sep 19. No abstract available.

PMID:
27643867
21.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Morton LM, Saber W, Baker KS, Barrett AJ, Bhatia S, Engels EA, Gadalla SM, Kleiner DE, Pavletic S, Burns LJ.

Biol Blood Marrow Transplant. 2017 Mar;23(3):367-378. doi: 10.1016/j.bbmt.2016.09.005. Epub 2016 Sep 12.

22.

Improved reproducibility and quality of GvHD biomarker assay: application of multiplex microfluidic channel system.

Anandi P, Tian X, Chinian F, Cantilena CR, Dunavin N, Hensel N, Draper D, Koklanaris E, Maxwell S, Superata J, Muranski P, Battiwalla M, Paczesny S, Barrett AJ, Ito S.

Bone Marrow Transplant. 2016 Dec;51(12):1615-1616. doi: 10.1038/bmt.2016.226. Epub 2016 Sep 5. No abstract available.

PMID:
27595279
23.

Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.

Whitehill GD, Amarnath S, Muranski P, Keyvanfar K, Battiwalla M, Barrett AJ, Chinnassamy D.

Mol Ther. 2016 Sep;24(9):1655-64. doi: 10.1038/mt.2016.147. Epub 2016 Jul 6.

24.

When the Minimal Becomes Measurable.

Hourigan CS, Goswami M, Battiwalla M, Barrett AJ, Sheela S, Karp JE, Lai C.

J Clin Oncol. 2016 Jul 20;34(21):2557-8. doi: 10.1200/JCO.2016.67.6395. Epub 2016 May 16. No abstract available.

PMID:
27185839
25.

Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.

Tanaka H, Fujiwara H, Ochi F, Tanimoto K, Casey N, Okamoto S, Mineno J, Kuzushima K, Shiku H, Sugiyama T, Barrett AJ, Yasukawa M.

Clin Cancer Res. 2016 Sep 1;22(17):4405-16. doi: 10.1158/1078-0432.CCR-15-2714. Epub 2016 Apr 18.

26.

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, Lazarus HM, Seftel M, Saber W, Marks D, Aljurf M, Norkin M, Wingard JR, Lindemans CA, Boeckh M, Riches ML, Auletta JJ.

Blood. 2016 May 19;127(20):2427-38. doi: 10.1182/blood-2015-11-679639. Epub 2016 Feb 16.

27.

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).

Ishii K, Barrett AJ.

Ther Adv Hematol. 2016 Feb;7(1):17-39. doi: 10.1177/2040620715616544. Review.

28.

A Rare Consequence of Chronic Graft Versus Host Disease - Peyronie's Disease.

Jain NA, Venkatesan K, Anandi P, Ito S, Kumar D, Lu K, Battiwalla M, Barrett AJ.

Arch Cancer Res. 2015;3(2). pii: 18.

29.

Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.

Dumitriu B, Ito S, Feng X, Stephens N, Yunce M, Kajigaya S, Melenhorst JJ, Rios O, Scheinberg P, Chinian F, Keyvanfar K, Battiwalla M, Wu CO, Maric I, Xi L, Raffeld M, Muranski P, Townsley DM, Young NS, Barrett AJ, Scheinberg P.

Lancet Haematol. 2016 Jan;3(1):e22-9. doi: 10.1016/S2352-3026(15)00227-6. Epub 2015 Dec 17.

30.

Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia.

Hosokawa K, Muranski P, Feng X, Townsley DM, Liu B, Knickelbein J, Keyvanfar K, Dumitriu B, Ito S, Kajigaya S, Taylor JG 6th, Kaplan MJ, Nussenblatt RB, Barrett AJ, O'Shea J, Young NS.

J Immunol. 2016 Feb 15;196(4):1568-78. doi: 10.4049/jimmunol.1501739. Epub 2016 Jan 13.

31.

Tailoring steroid-sensitive virus-specific T cells with TALEN.

Barrett AJ.

Blood. 2015 Dec 24;126(26):2767-8. doi: 10.1182/blood-2015-11-679837. No abstract available.

32.

Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors.

Rawlings ND, Barrett AJ, Finn R.

Nucleic Acids Res. 2016 Jan 4;44(D1):D343-50. doi: 10.1093/nar/gkv1118. Epub 2015 Nov 2.

33.

Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency.

Salem B, Miner S, Hensel NF, Battiwalla M, Keyvanfar K, Stroncek DF, Gee AP, Hanley PJ, Bollard CM, Ito S, Barrett AJ.

Cytotherapy. 2015 Dec;17(12):1675-86. doi: 10.1016/j.jcyt.2015.08.008. Epub 2015 Sep 28.

34.

Identification of novel microRNA signatures linked to acquired aplastic anemia.

Hosokawa K, Muranski P, Feng X, Keyvanfar K, Townsley DM, Dumitriu B, Chen J, Kajigaya S, Taylor JG, Hourigan CS, Barrett AJ, Young NS.

Haematologica. 2015 Dec;100(12):1534-45. doi: 10.3324/haematol.2015.126128. Epub 2015 Sep 9.

35.

CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.

Anand A, Anandi P, Jain NA, Lu K, Dunavin N, Hourigan CS, Le RQ, Chokshi PD, Ito S, Stroncek DF, Sabatino M, Barrett AJ, Battiwalla M.

Support Care Cancer. 2016 Feb;24(2):815-822. doi: 10.1007/s00520-015-2848-9. Epub 2015 Jul 21.

36.

The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.

Barrett AJ, Bollard CM.

Ann Transl Med. 2015 Apr;3(5):62. doi: 10.3978/j.issn.2305-5839.2015.01.18. No abstract available.

37.

CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.

Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM.

Sci Transl Med. 2015 Apr 29;7(285):285ra63. doi: 10.1126/scitranslmed.aaa2546. Erratum in: Sci Transl Med. 2016 Jan 13;8(321):321er1.

38.

The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Barrett AJ, Ito S.

Blood. 2015 May 21;125(21):3230-5. doi: 10.1182/blood-2014-10-567784. Epub 2015 Apr 7. Review.

39.

Cytotoxic T lymphocytes for leukemia and lymphoma.

Bollard CM, Barrett AJ.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):565-9. doi: 10.1182/asheducation-2014.1.565. Epub 2014 Nov 18. Review.

PMID:
25696912
40.

A multigene array for measurable residual disease detection in AML patients undergoing SCT.

Goswami M, McGowan KS, Lu K, Jain N, Candia J, Hensel NF, Tang J, Calvo KR, Battiwalla M, Barrett AJ, Hourigan CS.

Bone Marrow Transplant. 2015 May;50(5):642-51. doi: 10.1038/bmt.2014.326. Epub 2015 Feb 9.

41.

A new checkpoint in the path to GVHD? How bedside-to-bench stem cell transplant studies can inform human GVHD biology.

Barrett AJ.

J Leukoc Biol. 2015 Feb;97(2):213-5. doi: 10.1189/jlb.5CE0814-385. No abstract available.

42.

ST2: the biomarker at the heart of GVHD severity.

Ito S, Barrett AJ.

Blood. 2015 Jan 1;125(1):10-1. doi: 10.1182/blood-2014-11-611780. No abstract available.

43.

Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.

Ito S, Barrett AJ, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, Larochelle A, Melenhorst JJ.

Stem Cell Res. 2015 Jan;14(1):95-104. doi: 10.1016/j.scr.2014.11.007. Epub 2014 Dec 6.

44.

Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo.

Amarnath S, Foley JE, Farthing DE, Gress RE, Laurence A, Eckhaus MA, Métais JY, Rose JJ, Hakim FT, Felizardo TC, Cheng AV, Robey PG, Stroncek DE, Sabatino M, Battiwalla M, Ito S, Fowler DH, Barrett AJ.

Stem Cells. 2015 Apr;33(4):1200-12. doi: 10.1002/stem.1934.

45.

Using the MEROPS Database for Proteolytic Enzymes and Their Inhibitors and Substrates.

Rawlings ND, Barrett AJ, Bateman A.

Curr Protoc Bioinformatics. 2014 Dec 12;48:1.25.1-33. doi: 10.1002/0471250953.bi0125s48.

PMID:
25501939
46.

Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.

Jain NA, Ito S, Tian X, Kurlander R, Battiwalla M, Lu K, Savani BN, Malkovska V, Rezvani K, Le RQ, Shenoy A, Hourigan CS, Keyvanfar K, Koklanaris E, Superata J, Muranski P, Barrett AJ, Yong ASM.

Bone Marrow Transplant. 2015 Feb;50(2):189-196. doi: 10.1038/bmt.2014.249. Epub 2014 Nov 10.

47.

Stem cell transplants for myelodysplastic syndromes: refining the outcome predictions.

Barrett AJ.

Haematologica. 2014 Oct;99(10):1536-7. doi: 10.3324/haematol.2014.113555. No abstract available.

48.

Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM.

Mol Ther. 2015 Jan;23(1):179-83. doi: 10.1038/mt.2014.192. Epub 2014 Sep 30.

49.

Persistence of Pseudomonas aeruginosa in a pulmonary nodule with late relapse.

Ronkainen S, Xie Y, Battiwalla M, Barrett AJ, Stock F, Dekker JP, Danner RL.

Transpl Infect Dis. 2014 Aug;16(4):666-71. doi: 10.1111/tid.12253. Epub 2014 Jun 26.

50.

Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Davies JOJ, Stringaris K, Barrett AJ, Rezvani K.

Cytotherapy. 2014 Nov;16(11):1453-1466. doi: 10.1016/j.jcyt.2014.03.009. Epub 2014 May 20. Review.

Supplemental Content

Loading ...
Support Center